Manager TitleAgeSince
Chief Executive Officer 60 -
Chief Operating Officer 56 2022-03-22
Chief Tech/Sci/R&D Officer 47 2021-04-30
Director TitleAgeSince
Director/Board Member - 2023-01-10
Director/Board Member 49 2023-01-10
Director/Board Member 60 -
Date Insider Type Main position Quantity % Market Cap. Importance
1/11/23 Tender

Controller/Auditor

227,744 0.6734%
1/11/23 Tender

Director

150,638 0.4454%
1/11/23 Issuer sale

Director

154,760 0.4576%
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%+0.08% - - 1.22B
+0.19%-2.90%+56.40%+69.15% 65.45B
-0.14%-3.20%+7.62%+90.41% 58.93B
+0.06%+0.15%+25.94%+86.73% 55.21B
-0.78%-3.38%+13.59%+113.90% 46.1B
-2.19%-6.55%+16.49%+23.41% 42.49B
+3.61%+3.86%+22.82%+46.39% 35.56B
+0.61%-8.23%+129.45%+644.73% 34.57B
+0.03%-0.93%+76.71%+57.52% 32.46B
+19.19%+20.27%-30.24%+476.77% 26.28B
Average +2.15%-2.93%+35.42%+178.78% 44B
Weighted average by Cap. +1.47%-2.69%+34.96%+149.15%
Logo Imago BioSciences, Inc.
Imago BioSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. It focuses on providing treatment for patients with cancer and bone marrow diseases. The Company's lead product candidate is bomedemstat, which is developed for the treatment of myeloproliferative neoplasms (MPNs), a chronic cancer of the bone marrow. The Company's product candidate, bomedemstat, is in Phase II clinical trial for the treatment of essential thrombocythemia (ET). The Company also develops bomedemstat and other LSD1-targeting product candidates for additional indications in areas of unmet medical need. It tests bomedemstat in mouse models of MPNs as a single agent.
Employees
41
  1. Stock Market
  2. Stocks
  3. IMGO Stock